NewNo. 014
Retatrutide Pen
Synedica pre-filled pen: 40 mg retatrutide, with needles
- Size
- 40 mg pen
- HPLC
- 99.752%
- Lot
- 07022601
ALTA PEPTIDES supplies research peptides for laboratory use only. You must be at least 18 to enter.
By entering you agree these products are for research use only and not for human consumption.
Pre-filled pen: 40 mg tirzepatide, GIP / GLP-1 dual receptor agonist
Lot certificate published at release
A sealed pre-filled pen holding 40 mg of tirzepatide, the 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. Arriving soon in UK stock; register to hear the price and release date first.
Tirzepatide is a synthetic peptide, 39 amino acids long, that switches on two hormone receptors at once: GIP and GLP-1. Both hormones are released by the gut after a meal. GLP-1 slows the stomach and reduces appetite; GIP supports insulin release and appears to strengthen the appetite effect. A fatty-acid side chain lets the tirzepatide peptide bind to albumin in the blood, which gives it a half-life of about five days.
It was developed by Eli Lilly under the code LY3298176 and is the active ingredient in the licensed medicines Mounjaro and Zepbound. Our GLP-1 receptor agonists explainer covers how this family of peptides was engineered.
In SURMOUNT-1, a 72-week trial in 2,539 adults with obesity published in the New England Journal of Medicine in 2022, average body-weight loss was 15.0%, 19.5% and 20.9% in the three tirzepatide arms, against 3.1% on placebo. In SURMOUNT-5, a head-to-head trial published in 2025, tirzepatide produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide. The most common side effects reported in the trials were nausea, diarrhoea, vomiting and constipation.
The three differ in how many receptors they act on. Semaglutide acts on one (GLP-1), tirzepatide on two (GIP and GLP-1) and retatrutide on three (GIP, GLP-1 and glucagon). In separate trials each step added weight loss: 14.9% for semaglutide (STEP 1, 68 weeks), 20.9% for tirzepatide (SURMOUNT-1, 72 weeks) and 28.3% for retatrutide (TRIUMPH-1, 80 weeks). Our retatrutide vs tirzepatide vs semaglutide comparison sets the trials side by side. The semaglutide pen is also coming soon, and the retatrutide pen and retatrutide vials are in stock now.
The tirzepatide pen is a sealed, pre-filled pen containing 40 mg of tirzepatide in solution, filled by the manufacturer, not by ALTA PEPTIDES. A pen arrives ready-made, where a tirzepatide vial is a dry powder that a laboratory reconstitutes itself. Our pen vs vial guide explains the trade-offs, which are the same for every peptide in this class. The certificate of analysis for the tirzepatide in each lot will be published on this page before the pen goes on sale.
Tirzepatide is the active ingredient in Mounjaro, a prescription-only medicine licensed in the UK for type 2 diabetes and weight management. This pen is not Mounjaro, is not made or endorsed by Eli Lilly, and is not a medicine. It is research-grade tirzepatide supplied for laboratory research only, not for human use. Anyone seeking treatment should speak to a doctor or a registered pharmacy. Our guide to UK peptide law explains the difference between licensed medicines and research compounds.
The tirzepatide 40 mg pen is arriving soon in UK stock. The price, release date and lot certificate will be posted here first. Register above to be told the day it is available.
Tirzepatide has become the reference compound, or comparator, that newer incretin drugs are measured against. A phase 3 study registered on ClinicalTrials.gov (NCT06662383) compares retatrutide with tirzepatide in adults who have obesity. CagriSema, Novo Nordisk's amylin combination, was tested against tirzepatide in the REDEFINE 4 trial, which our amylin agonists explainer covers.
The UK prescribing information for Mounjaro sets out why the molecule matters to the study of metabolic regulation. It states that GIP and GLP-1 receptors are both expressed in the areas of the brain important to appetite regulation. It also reports an in-vitro finding: in cultured human adipocytes, tirzepatide acts on GIP receptors to regulate glucose uptake.
None of that research was done with the pen on this page. For UK researchers the position is unchanged. This UK research peptide listing is not held in ALTA PEPTIDES UK stock, it is not Mounjaro and it is not a licensed medicine. Its certificate of analysis will be published here before the pen goes on sale. It is listed for research purposes, strictly for laboratory research, and ALTA gives no guidance on human use.
NewNo. 014
Synedica pre-filled pen: 40 mg retatrutide, with needles
NewNo. 013
GLP-1 / GIP / glucagon triple receptor agonist